Original Article Comparison of [18F]fluorocholine PET/CT with [99mTc]sestamibi and ultrasonography to detect parathyroid lesions in primary hyperparathyroidism: a prospective study Marti Manyalich-Blasi, Paula Domínguez-Garijo, David Saavedra-Pérez, Nuria Sánchez-Izquierdo, Sebastián Casanueva Eliceiry, Andrés Perissinotti, Mireia Mora Porta, Ana de Hollanda, Felicia A. Hanzu, Miquel A. López-Boado Serrat, Antonio R. Rull Ortuño, Jordi Ardid, Sergi Vidal-Sicart, Òscar Vidal Pérez
Purpose: To evaluate the diagnostic accuracy and detection rate of lymph node metastases (LNM) in Papillary Thyroid Carcinoma (PTC) using the One-Step Nucleic Acid Amplification (OSNA) technique compared to conventional pathological methods. Methods: A systematic search was conducted in PubMed, The Cochrane Library, Scopus, and Web of Science from May 1, 2023, to June 30, 2023, for studies published from January 1, 2005, to April 30, 2023. Observational studies assessing OSNA for LNM in PTC patients were included. Two independent reviewers performed study selection, record screening, data extraction, and quality assessment using QUADAS-2. Meta-analysis was conducted with Posit software (RStudio). Results: Seven studies (2014–2021) involving 1,424 lymph nodes from 207 PTC patients were analyzed. The pooled sensitivity, specificity, and AUC of OSNA for detecting LNM were 0.905 (95% CI 0.838–0.946), 0.884 (95% CI 0.834–0.921), and 0.848, respectively. Discussion: OSNA shows promising diagnostic accuracy compared to conventional pathological methods, with the potential to improve real-time lymphatic staging and aid intraoperative decision-making. Limitations include study heterogeneity and a lack of randomized controlled trials, affecting generalizability. Further research is needed to validate the long-term benefits of OSNA in clinical practice.
Robot-assisted surgery has revolutionized minimally invasive procedures, offering superior three-dimensional visualization and mobile instruments suitable for smaller areas. For this reason, robotic retroperitoneal adrenalectomy (RRA) is emerging as an ideal procedure for this technology. This study aimed to assess the outcomes of the first 10 consecutive cases of this procedure using the RAS Hugo™ platform. Conducted between July 2023 and February 2024, the surgeries were performed with patients in the prone position, accessing the retroperitoneal space using standard endoscopic techniques. High-energy sealing instruments were utilized for adrenal vein sectioning, and specimens were extracted using protective bags. Ten surgical interventions were performed, with six male patients and four female patients. Most patients underwent surgery due to suspected primary hyperaldosteronism ( n =7), while the remainder were operated on for Cushing’s syndrome ( n =3). Median patient age was 58 years (range 50–73) with a median BMI of 28.5 kg/m 2 (range 21–36), and American Society of Anaesthesiologists (ASA) risk scores were evenly split between ASA II and ASA III. Lesions were equally distributed between the right and left adrenal glands, with a median tumor size of 1.5 cm (range 0.5–3.5). Median operative time was 124.5 min (range 102–198), with one case requiring conversion to endoscopic approach due to pyelonephritis. No postoperative complications were reported, and median hospital stay was 1 day (range 1–3). RRA demonstrates feasibility for selected patients, offering enhanced image resolution and precision in confined spaces. However, challenges such as increased operative time and the need for skilled teams warrant consideration.
Background/Objectives: Given the high incidence and generally favorable prognosis of papillary thyroid microcarcinomas (PTMs), the Porto Proposal aims to refine the management of these tumors. It designates tumors lacking certain risk factors as papillary microtumors (PMTs) to avoid overtreatment and reduce patient stress. The updated Porto Proposal (uPp) suggests criteria for reclassifying incidental PTMs as PMTs. This study seeks to validate these criteria using data from a university hospital in Catalonia, Spain, and assess the clinical and pathological characteristics of PTMs. Methods: This retrospective study analyzed patients diagnosed with PTM (≤1 cm) at a university hospital from 2000 to 2024. The study examined variables, including lymph node positivity, incidental diagnosis, tumor location, histological type, treatment, multifocality, age at diagnosis, tumor size, and survival. The uPp criteria were applied to reclassify PTMs into PMTs or PMCs (true papillary microcarcinomas). Student’s t-test and chi-square tests were used to evaluate the associations between these variables and the uPp classification. Results: The cohort comprised 107 patients, with 77 (72%) women and 30 men. The mean age at diagnosis was 54.5 years. Out of the total, 77 (72%) cases were reclassified as PMTs and 30 (28%) as PMCs according to the uPp criteria. PMC tumors were larger (mean size 4.5 mm vs. 3.3 mm for PMT, p = 0.014) and were significantly associated with multifocality (52.2%; p = 0.004). Most lymph node-positive cases were classified as PMCs (69.2%; p < 0.001) and were multifocal and bilateral more commonly. However, no significant differences in outcomes between PMCs and PMTs were found (p = 0.188). Follicular histology was significantly more common in PMTs (87.0%, p < 0.001) and rarely had lymph node metastases (4.6%; p = 0.047). Conclusions: The updated Porto Proposal (uPp) effectively identifies PTMs with minimal malignant potential, distinguishing between PMT and PMC. The findings support the protocol’s use in reducing unnecessary treatments and psychological stress for patients. The study highlights significant clinical and pathological differences between PTM subtypes, reinforcing the protocol’s applicability in daily pathological practice.